Surrozen Inc (SRZN) Actualités

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”...

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients...

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”...

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented...

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment...

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in...

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate...

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal...

Surrozen Provides First Quarter 2024 Financial Results and Business Update

SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the...

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase...

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

-   $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of...